| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.1 | 0.03 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.078 | 0.03 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | 0.079 | 0.03 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.096 | 0.03 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.076 | 0.03 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.03 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.03 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.076 | 0.03 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.03 |